Pacific Biosciences
PACB
274 hedge funds and large institutions have $2.2B invested in Pacific Biosciences in 2023 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 92 increasing their positions, 86 reducing their positions, and 40 closing their positions.
307% more call options, than puts
Call options by funds: $101M | Put options by funds: $24.8M
2.87% more ownership
Funds ownership: 101.55% → 104.41% (+2.9%)
8% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 40
7% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 86
1% more funds holding
Funds holding: 272 → 274 (+2)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
35% less capital invested
Capital invested by funds: $3.37B → $2.2B (-$1.18B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$52M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$36.4M |
| 3 |
VS
VK Services
Menlo Park,
California
|
+$30.1M |
| 4 |
Bank of New York Mellon
New York
|
+$28.7M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.5M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$37.7M |
| 3 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$18.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$13.6M |
| 5 |
SIG
Senator Investment Group
New York
|
-$13.3M |
PACB Hedge Fund Activity: Q3 2023 in Review
274 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2023, worth a combined $2.2B — down 35% from $3.37B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new PACB positions and 40 closed out — a net gain of 3 holders — while 92 added to existing stakes and 86 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $52M. The largest seller was Point72 Asset Management, cutting an estimated $46.5M.
- 274 institutional investors held Pacific Biosciences (PACB) as of Q3 2023, up from 272 in Q2 2023.
- Funds reported $2.2B of Pacific Biosciences stock for Q3 2023, down 35% quarter-over-quarter.
- 43 funds opened new Pacific Biosciences positions in Q3 2023 and 40 closed out, a net change of +3 holders.
- The largest Pacific Biosciences buyer in Q3 2023 was Deep Track Capital, an estimated $52M added.
- The largest Pacific Biosciences seller in Q3 2023 was Point72 Asset Management, an estimated $46.5M sold.
Based on aggregated 13F filings for Q3 2023.